All In Biotech

Drug Trial Radar · NCT03600441

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)

Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

139

Planned (sponsor's estimate)

Start

Aug 27, 2018

Primary completion

Dec 31, 2027

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Xynomic Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.

Conditions

  • Follicular Lymphoma

Interventions

  • AbexinostatDrug

    Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical effect of abexinostatTime frame: Time frame up to 100 months

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Advocate Medical Group - Park Ridge, Luther Lane - Oncology

    Park Ridge, Illinois

  • Norton Cancer Institute - St. Matthews Campus

    Louisville, Kentucky

  • Clinical Research Alliance Inc

    Lake Success, New York

  • Manhattan Hematology Oncology Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Bone Marrow Transplant Hematology Oncology Associates

    Pittsburgh, Pennsylvania

  • Arlington Cancer Center

    Arlington, Texas

  • Central Texas Veterans Health Care System - NAVREF

    Temple, Texas

  • Vista Oncology Inc. PS

    Olympia, Washington

  • Centre Hospitalier de Perpignan

    Perpignan, Pyrénées-Orientales, France

  • Hospital Universitario Vall d'Hebrón

    Barcelona, Spain

  • Hospital del Mar

    Barcelona, Spain

  • C.H. Regional Reina Sofia

    Córdoba, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, Spain

  • Hospital Universitario de Donostia

    Donostia / San Sebastian, Guipúzcoa, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.